Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cadonilimab + regorafenib + gemcitabine + cisplatin
- Development stage
- Preclinical
- Lead developer
- Kangfang Sainuo Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a four-drug combination regimen consisting of cadonilimab, regorafenib, gemcitabine, and cisplatin. - **Cadonilimab** is a bispecific monoclonal antibody targeting both PD-1 and CTLA-4 immune checkpoints to enhance anti-tumor immune responses. - **Regorafenib** is an oral small molecule multikinase inhibitor that targets angiogenic, stromal, and oncogenic receptor tyrosine kinases involved in tumor growth and progression. - **Gemcitabine** is a nucleoside analog antimetabolite that inhibits DNA synthesis in rapidly dividing cells. - **Cisplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in cancer cells. This combination brings together immunotherapy with targeted therapy and cytotoxic chemotherapy for synergistic anti-cancer effects.
- Brand names
- Lenvatux
- Other names
- AK104AK-104AK 104BAY 73-4506BAY73-4506BAY-73-4506
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)RAF1 (c-Raf-1 (Y340D/Y341D))CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on cadonilimab + regorafenib + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cadonilimab + regorafenib + gemcitabine + cisplatin.